Hikma Beats GSK, Pfizer In Argatroban IP Infringement Row

Law360, New York (July 31, 2012, 7:17 PM EDT) -- GlaxoSmithKline PLC and Pfizer Inc. on Tuesday failed to stop Hikma Pharmaceutical Co. Ltd. from selling a generic version of anti-coagulant Argatroban after a New Jersey federal judge ruled the company hadn't infringed a patent associated with the drug.

U.S. District Judge Freda L. Wolfson granted Hikma's request for a declaration that the company didn't infringe a patent assigned to both GSK and Pfizer, while denying the companies' request for a judgment of infringement.

Judge Wolfson, however, also deflected Hikma's request for a declaration that the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.